Polymorphisms in carcinogen metabolism enzymes, fish intake, and risk of prostate cancer

Carcinogenesis

Volumn 33, Issue 7, 2012, Pages 1352-1359

  Catsburg, Chelsea ^a   Joshi, Amit D ^a   Corral, Román ^a   Lewinger, Juan Pablo ^a   Koo, Jocelyn ^b   John, Esther M ^b,c   Ingles, Sue A ^a   Stern, Mariana C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; EPHX1 PROTEIN; GLUCURONOSYLTRANSFERASE 1A6; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; PTGS2 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CALORIC INTAKE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; COOKING; COPY NUMBER VARIATION; ETHNICITY; FISH MEAT; FOOD INTAKE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; CARCINOGENS; FISHES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; SEAFOOD;

EID: 84865189680     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs175     Document Type: Article

References (61)

1. Augustsson,K. et al. (2003) A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 12, 64-67.
2. Chavarro,J.E. et al. (2008) A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality. Am. J. Clin. Nutr., 88, 1297-1303.
3. Pham,T.M. et al. (2009) Fish intake and the risk of fatal prostate cancer: findings from a cohort study in Japan. Public Health Nutr., 12, 609-613.
4. Terry,P. et al. (2001) Fatty fish consumption and risk of prostate cancer. Lancet, 357, 1764-1766.
5. Wendel,M. et al. (2009) Anticancer actions of omega-3 fatty acids-current state and future perspectives. Anticancer Agents Med. Chem., 9, 457-470.
6. Richman,E.L. et al. (2010) Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am. J. Clin. Nutr., 91, 712-721.
7. Schuurman,A.G. et al. (1999) Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. Br. J. Cancer, 80, 1107-1113.
8. Sonoda,T. et al. (2004) A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci., 95, 238-242.
9. Allen,N.E. et al. (2004) A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control, 15, 911-920.
10. Joshi,A.D. et al. (2012) Fish intake, cooking practices, and risk of prostate cancer: results from a multi-ethnic case-control study. Cancer Causes Control, 23, 405-420.
11. International Agency for Research on Cancer (IARC) (1993). Summaries and evaluations PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) (Group 2B), vol. 56.
12. Shirai,T. et al. (1997) The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res., 57, 195-198.
13. Stuart,G.R. et al. (2000) Prostate mutations in rats induced by the suspected human carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res., 60, 266-268.
14. Rybicki,B.A. et al. (2004) Polycyclic aromatic hydrocarbon-DNA adducts in prostate cancer. Cancer Res., 64, 8854-8859.
15. Aeschbacher,H.U. et al. (1989) Effect of heterocyclic amines and beef extract on chromosome aberrations and sister chromatid exchanges in cultured human lymphocytes. Carcinogenesis, 10, 429-433.
16. Moonen,H.J. et al. (2002) Generation of free radicals and induction of DNA adducts by activation of heterocyclic aromatic amines via different metabolic pathways in vitro. Mol. Carcinog., 35, 196-203.
17. Williams,J.A. et al. (2000) Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis, 21, 1683-1689.
18. Di Paolo,O.A. et al. (2005) Expression of cytochromes P450 and glutathione S-transferases in human prostate, and the potential for activation of heterocyclic amine carcinogens via acetyl-coA-, PAPS- and ATPdependent pathways. Int. J. Cancer, 117, 8-13.
19. Shimada,T. et al. (2004) Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci., 95, 1-6.
20. Bock,K.W. et al. (1999) Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases. Drug Metab. Rev., 31, 411-422.
21. Kirschenbaum,A. et al. (2000) Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology, 56, 671-676.
22. Wang,W. et al. (2004) Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate, 61, 60-72.
23. Rybicki,B.A. et al. (2006) Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis. Cancer Lett., 239, 157-167.
24. Strange,R.C. et al. (1999) The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC Sci. Publ., 148, 231-249.
25. Srivastava,D.S. et al. (2005) Genetic polymorphism of glutathione S-transferase genes (GSTM1, GSTT1 and GSTP1) and susceptibility to prostate cancer in Northern India. BJU Int., 95, 170-173.
26. Papafili,A. et al. (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler. Thromb. Vasc. Biol., 22, 1631-1636.
27. Sachse,C. et al. (2003) Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br. J. Clin. Pharmacol., 55, 68-76.
28. Hassett,C. et al. (1997) Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch. Biochem. Biophys., 337, 275-283.
29. Tang,Y.M. et al. (2000) Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics, 10, 761-766.
30. MacLeod,S.L. et al. (2000) Genetic polymorphisms. In Nagao,M. and Sugimura,H. (eds) Food Borne Carcinogens: Heterocyclic Amines. John Wiley & Sons, West Sussex, UK, pp. 112-130.
31. Hirvonen,A. (1999) Polymorphic NATs and cancer predisposition. IARC Sci. Publ., 251-270.
32. John,E.M. et al. (2005) Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res., 65, 5470-5479.
33. Schwartz,G.G. et al. (2010) Prostate cancer in African-American men and polymorphism in the calcium-sensing receptor. Cancer Biol. Ther., 9, 994-999.
34. Pike,M.C. et al. (1997) Estrogen-progestin replacement therapy and endometrial cancer. J. Natl. Cancer Inst., 89, 1110-1116.
35. John,E.M. et al. (2011) Meat consumption, cooking practices, meat mutagens, and risk of prostate cancer. Nutr. Cancer, 63, 525-537.
36. Sinha,R. et al. (2005) Development of a food frequency questionnaire module and databases for compounds in cooked and processed meats. Mol. Nutr. Food Res., 49, 648-655.
37. Willett,W.C. et al. (1997) Adjustment for total energy intake in epidemiologic studies. Am. J. Clin. Nutr., 65, 1220S-1228S; discussion 1229S-1231S.
38. Hein,D.W. et al. (2012) Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics, 13, 31-41.
39. Hein,D.W. et al. (2000) Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics, 10, 291-292.
40. Gauderman,W.J. (2002) Sample size requirements for association studies of gene-gene interaction. Am. J. Epidemiol., 155, 478-484.
41. Carnell,D.M. et al. (2004) Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int. J. Radiat. Oncol. Biol. Phys., 58, 500-509.
42. Martin,F.L. et al. (2010) Constitutive expression of bioactivating enzymes in normal human prostate suggests a capability to activate pro-carcinogens to DNA-damaging metabolites. Prostate, 70, 1586-1599.
43. Fukatsu,T. et al. (2004) Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res., 24, 2431-2437.
44. Beuten,J. et al. (2008) CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis, 29, 1751-1757.
45. Pastorelli,R. et al. (1998) Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrenediolepoxide. Cancer Epidemiol. Biomarkers Prev., 7, 703-709.
46. Penning,T.M. et al. (1999) Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones. Chem. Res. Toxicol., 12, 1-18.
47. Mittal,R.D. et al. (2007) Cytochrome P4501A1 and microsomal epoxide hydrolase gene polymorphisms: gene-environment interaction and risk of prostate cancer. DNA Cell Biol., 26, 791-798.
48. Figer,A. et al. (2003) Analysis of polymorphic patterns in candidate genes in Israeli patients with prostate cancer. Isr. Med. Assoc. J., 5, 741-745.
49. Mo,Z. et al. (2009) An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate, 69, 662-688.
50. Norskov,M.S. et al. (2011) Copy number variation in glutathione-S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population. Pharmacogenomics J., 11, 292-299.
51. Souiden,Y. et al. (2010) Polymorphisms of glutathione-S-transferase M1 and T1 and prostate cancer risk in a Tunisian population. Cancer Epidemiol., 34, 598-603.
52. Safarinejad,M.R. et al. (2011) Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) and prostate cancer: a case-control study in Tehran, Iran. Prostate Cancer Prostatic Dis., 14, 105-113.
53. Taioli,E. et al. (2011) Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis, 32, 1361-1365.
54. Steinbrecher,A. et al. (2010) Dietary glucosinolate intake, polymorphisms in selected biotransformation enzymes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 19, 135-143.
55. Lavender,N.A. et al. (2009) Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among men of African descent: a case-control study. BMC Cancer, 9, 397.
56. Fradet,V. et al. (2009) Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin. Cancer Res., 15, 2559-2566.
57. Hedelin,M. et al. (2007) Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int. J. Cancer, 120, 398-405.
58. Lim,K. et al. (2009) Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase- Mol. Cancer Ther., 8, 3046-3055.
59. Cui,J.G. et al. (2005) Characterization of a cyclooxygenase-2-765G->C promoter polymorphism in human neural cells. Neuroreport, 16, 575-579.
60. Sanak,M. et al. (2010) Functional promoter polymorphism of cyclooxygenase-2 modulates the inflammatory response in stable coronary heart disease. Pol. Arch. Med. Wewn., 120, 82-88.
61. Salmon,C.P. et al. (1997) Effects of marinating on heterocyclic amine carcinogen formation in grilled chicken. Food Chem. Toxicol., 35, 433-441.